NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers

Zheng, Lei; Wang, Guiyu; Guo, Wei; Pan, Deng; Xie, Laiping; He, Song; Luo, Can; Li, Hongmin; Ran, Yaling; Wu, Shiyang; Liu, Fang; Zhang, Xiaoli; Huang, Dingde

doi:10.1007/s11033-019-04873-w

Cited by 7 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a pilot study, an early decrease in CEC counts after RAI treatment correlates with disease response in DTC patients [ 55 ]. Zheng and colleagues investigated sodium/iodide symporter (NIS) expression in CTCs from DTC patients and found a correlation between a decreased or unchanged number of total NIS+ CTCs and the efficacy of RAI therapy [ 56 ].…”

Section: Liquid Biopsy In Differentiated Thyroid Cancermentioning

confidence: 99%

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer

Romano

Martorana

Pennisi

et al. 2021

IJMS

View full text Add to dashboard Cite

Thyroid cancer is the most common malignancy of the endocrine system, encompassing different entities with distinct histological features and clinical behavior. The diagnostic definition, therapeutic approach, and follow-up of thyroid cancers display some controversial aspects that represent unmet medical needs. Liquid biopsy is a non-invasive approach that detects and analyzes biological samples released from the tumor into the bloodstream. With the use of different technologies, tumor cells, free nucleic acids, and extracellular vesicles can be retrieved in the serum of cancer patients and valuable molecular information can be obtained. Recently, a growing body of evidence is accumulating concerning the use of liquid biopsy in thyroid cancer, as it can be exploited to define a patient’s diagnosis, estimate their prognosis, and monitor tumor recurrence or treatment response. Indeed, liquid biopsy can be a valuable tool to overcome the limits of conventional management of thyroid malignancies. In this review, we summarize currently available data about liquid biopsy in differentiated, poorly differentiated/anaplastic, and medullary thyroid cancer, focusing on circulating tumor cells, circulating free nucleic acids, and extracellular vesicles.

show abstract

Section: Liquid Biopsy In Differentiated Thyroid Cancermentioning

confidence: 99%

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer

Romano

Martorana

Pennisi

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The finding revealed that the decrease in the amount of EpCAM+ circulating epithelial cells in the early stages of RAI therapy helped to identify patients who were sensitive to RAI treatment and suggested that CTCs may help ensure patients’ response to 131 I therapy. The sodium/iodide symporter (NIS) expression of CTCs was observed by Zheng et al [ 64 ], who discovered that reduced or stable total NIS+ CTCs following RAI treatment might suggest beneficial effectiveness or successful RAI therapy. Of note, the number of CTCs may be linked to the duration of radioiodine treatment, and the data show that compared to those < 8 years ago, CTCs are more common in DTC patients who received RAI therapy more than 8 years ago [ 60 ], which was the first study revealing the association between CTCs and the period since the last RAI therapy.…”

Section: Ctc and Its Clinical Applicationmentioning

confidence: 99%

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review

Wang,

Zheng,

Lei

2023

IJMS

View full text Add to dashboard Cite

Thyroid cancer has become more common in recent years all around the world. Many issues still need to be urgently addressed in the diagnosis, treatment, and prognosis of thyroid cancer. Liquid biopsy (mainly circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating exosomes) may provide a novel and ideal approach to solve these issues, allows us to assess the features of diseases more comprehensively, and has a function in a variety of malignancies. Recently, liquid biopsy has been shown to be critical in thyroid cancer diagnosis, treatment, and prognosis in numerous previous studies. In this review, by testing CTCs, ctDNA, and exosomes, we focus on the possible clinical role of liquid biopsy in thyroid cancer, including diagnostic and prognostic biomarkers and response to therapy. We briefly review how liquid biopsy components have progressed in thyroid cancer by consulting the existing public information. We also discuss the clinical potential of liquid biopsy in thyroid cancer and provide a reference for liquid biopsy research. Liquid biopsy has the potential to be a useful tool in the early detection, monitoring, or prediction of response to therapies and prognosis in thyroid cancer, with promising clinical applications.

show abstract

“…In this context, telomerase reverse transcriptase (TERT) promoter mutations have been proposed to assist identification of patients with poorly differentiated TC with high risk of RAI refractoriness (9). The same holds true for the assessment of sodium-iodide symporter expression in circulating tumor cells (10). Also, prostate-specific membrane antigen (PSMA) expression in tumor tissue has been suggested to contribute in the prediction of tumor aggressiveness and patient outcome (11).…”

Section: Introductionmentioning

confidence: 99%

IGF2 is a potential factor in RAI‑refractory differentiated thyroid cancer

et al. 2021

View full text Add to dashboard Cite

Differentiated thyroid cancer (DTC) is the most frequent endocrine tumor with a good prognosis after primary treatment in most cases. By contrast, 30–40% of patients with metastatic DTC are unresponsive to 131 I radioactive iodide (RAI) treatment due to tumor dedifferentiation. Currently, underlying molecular mechanisms of dedifferentiation remain elusive and predictive biomarkers are lacking. Therefore, the present study aimed to identify molecular biomarkers in primary tumors associated with RAI refractoriness. A retrospective cohort was gathered consisting of RAI-sensitive patients with DTC and RAI-refractory patients with poorly DTC. In all patients, extensive intratumoral mutation profiling, gene fusions analysis, telomerase reverse transcriptase (TERT) promoter mutation analysis and formalin-fixed paraffin-embedded-compatible RNA sequencing were performed. Genetic analyses revealed an increased mutational load in RAI-refractory DTC, including mutations in AKT1, PTEN, TP53 and TERT promoter. Transcriptomic analyses revealed profound differential expression of insulin-like growth factor 2 ( IGF2 ), with up to 100-fold higher expression in RAI-refractory DTC compared with in RAI-sensitive DTC cases. ELISA revealed significant lower IGF2 plasma concentrations after surgery and subsequent 131 I RAI therapy in patients with DTC compared with pretreatment baseline. Overall, the current findings suggested that the tumor-promoting growth factor IGF2 may have a potential role in acquiring RAI refractoriness.

show abstract

NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers

Cited by 7 publications

References 35 publications

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review

IGF2 is a potential factor in RAI‑refractory differentiated thyroid cancer

Contact Info

Product

Resources

About